Trials / Completed
CompletedNCT00152412
Open Study to Evaluate the Safety of Levocetirizine in Young Children (2 - 6 Years) Suffering From Allergic Rhinitis
A 4 Week Open, Multi-center Study Evaluating the Safety of Levocetirizine 1.25 mg b.i.d. Given as 0.5 mg/mL Oral Solution in 2 to 6 Year-old Children Suffering From Allergic Rhinitis.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (planned)
- Sponsor
- UCB Pharma · Industry
- Sex
- All
- Age
- 2 Years – 6 Years
- Healthy volunteers
- —
Summary
4 week open study to evaluate the safety of levocetirizine in young children (2 - 6 years) suffering from allergic rhinitis. As secondary objective, this study will assess the efficacy of the treatment by means of the T4SS (Total 4 symptoms scores of allergic rhinitis) and each of the 4 individual rhinitis symptom scores
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Levocetirizine oral solution |
Timeline
- Start date
- 2004-06-01
- Primary completion
- 2004-12-01
- Completion
- 2004-12-01
- First posted
- 2005-09-09
- Last updated
- 2014-08-26
Source: ClinicalTrials.gov record NCT00152412. Inclusion in this directory is not an endorsement.